Golf Clap for Teva Pharmaceutical Industries

Just the facts, Fool.

Seth Jayson
Seth Jayson
Feb 7, 2013 at 12:00AM
Other

Teva Pharmaceutical Industries (NYSE: TEVA) reported earnings on Feb. 7. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Teva Pharmaceutical Industries met expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue contracted and GAAP earnings per share shrank significantly.

Margins contracted across the board.

Revenue details
Teva Pharmaceutical Industries booked revenue of $5.25 billion. The 21 analysts polled by S&P Capital IQ anticipated revenue of $5.25 billion on the same basis. GAAP reported sales were 7.5% lower than the prior-year quarter's $5.68 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $1.32. The 24 earnings estimates compiled by S&P Capital IQ anticipated $1.33 per share. GAAP EPS of $0.37 for Q4 were 35% lower than the prior-year quarter's $0.57 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 53.1%, 390 basis points worse than the prior-year quarter. Operating margin was 18.5%, 810 basis points worse than the prior-year quarter. Net margin was 6.1%, 280 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $4.85 billion. On the bottom line, the average EPS estimate is $1.17.

Next year's average estimate for revenue is $20.17 billion. The average EPS estimate is $5.09.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,471 members out of 2,542 rating the stock outperform, and 71 members rating it underperform. Among 583 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 575 give Teva Pharmaceutical Industries a green thumbs-up, and eight give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Teva Pharmaceutical Industries is outperform, with an average price target of $46.62.

Can your portfolio provide you with enough income to last through retirement? You'll need more than Teva Pharmaceutical Industries. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.